
Ineffective Low-Dose Eyedrops Fail to Slow Myopia Progression
A randomized controlled trial funded by the National Eye Institute (NEI) found that low-dose atropine eyedrops (0.01%) were no more effective than a placebo in slowing the progression of myopia (nearsightedness) in children over a two-year period. The results contradict previous studies in East Asia that showed a benefit from low-dose atropine. The findings highlight the need for further research to identify effective strategies for managing myopia, which is becoming increasingly common and can lead to irreversible vision loss.

